Human Immunoglobulin G
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Human Immunoglobulin G: Toward Severe Nonproliferative Diabetic Retinopathy
Note: This evidence pack does not include an on-file “original indication” for Human Immunoglobulin G (drug.original_indications is empty; taiwan_regulatory.licenses is empty). The title format below therefore reflects only the predicted new indication; the original-use context could not be populated from the data provided.
One-Sentence Summary
Human Immunoglobulin G (DB00028) has no original indication or mechanism-of-action data on file in this evidence pack, and it is currently not marketed in the Canadian dataset reviewed (0 licenses/DINs). The TxGNN model predicts it may be effective for Severe Nonproliferative Diabetic Retinopathy, with a prediction score of 99.75%, but this is supported by 0 clinical trials and only 1 publication, which is itself a biomarker/observational study rather than treatment evidence. Given the evidence level (L5) and a blocking data gap on regulatory safety information, the recommended decision at this stage is Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no approved indication or license record on file) |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| Canada Market Status | Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Human Immunoglobulin G in this evidence pack (flagged as a High-severity data gap, DG002). Without MOA data and without a documented original indication, it is not possible to construct a pharmacological rationale linking this drug’s established use to diabetic retinopathy.
The only supporting literature identified (PMID 40204274) investigates serum IgG Fc N-glycosylation patterns as a potential diagnostic biomarker for distinguishing nonproliferative from proliferative diabetic retinopathy. This is a disease-staging correlation study, not a therapeutic intervention study — it shows that IgG glycosylation changes with disease state, not that administering IgG treats the disease. As the evidence pack’s own mechanistic assessment notes, this is an observational/correlative finding and cannot be used to support therapeutic use of IgG in this indication.
In short, the high TxGNN score (99.75%) appears to be driven by network-level embedding similarity rather than by any confirmed causal or mechanistic relationship. The prediction should be treated as a hypothesis-generating signal only, not as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40204274 | 2025 | Cross-sectional biomarker study | Molecular & Cellular Proteomics | Analyzed serum disease-specific IgG Fc N-glycosylation in 160 patients (47 non-diabetic retinopathy, 51 nonproliferative DR, 62 proliferative DR) to evaluate its potential as a diagnostic biomarker for distinguishing DR stages; does not evaluate IgG as a treatment. |
Canada Market Information
Human Immunoglobulin G is currently not marketed in the dataset reviewed — total_licenses is 0 and no license records are available, so no product/DIN table can be generated.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence level is L5 (model prediction only) — there are no clinical trials and only a single, non-interventional biomarker study supporting a link between IgG and severe nonproliferative diabetic retinopathy. Combined with the absence of mechanism-of-action data and the lack of any market/regulatory safety file, there is currently insufficient basis to advance this candidate beyond an early hypothesis.
To proceed, the following is needed:
- TFDA/regulatory label warnings and contraindications (Blocking data gap, DG001) — required before any Stage 1 safety screening can occur
- Mechanism of action (MOA) data via DrugBank API (High-severity data gap, DG002) — needed to assess mechanistic plausibility
- Interventional (not merely observational/biomarker) studies testing IgG administration in diabetic retinopathy
- Confirmation of Canadian market/regulatory status and any available product information, since no licenses are currently on file
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.